Feb 26, 2026
Media Highlights
Flagship-Backed Generate Biomedicines Raises $400 Million in IPO
View on: Bloomberg
Media Center
Jan 09, 2026
Media Highlights
PharmaVoice’s Crystal Ball: What’s next for AI and drug R&D
View on: PharmaVoice
Jan 02, 2026
Media Highlights
Long-acting anti-TSLP antibody for severe asthma moves into phase 3
View on: Healio
Dec 09, 2025
Media Highlights
What will be the first AI-designed drug? These disease-fighting antibodies are top contenders
View on: Nature
Dec 01, 2025
Media Highlights
Generate to launch Phase 3 TSLP drug studies, as AI bio enters its clinical era
View on: Endpoints News
Dec 01, 2025
Media Highlights
Somerville biotech says its AI-created asthma drug will enter late-stage trials
View on: Biz Journals
Oct 14, 2025
Media Highlights
Monoclonal antibody effects persist for 6 months in patients
View on: Healio
Oct 14, 2025
Media Highlights
Benchtalk 2025: Generate:Biomedicines’ VP of Informatics Stephen Kottmann describes the investments in technology that ensures only the highest quality data returns back into its models
View on: BiotechTV
Sep 22, 2025
Media Highlights
The Future of Medicine 2025: Boston’s breakthroughs in biotech
View on: Boston Globe